KAMILLA (NCT01702571) is a multicenter, phase IIIb trial of T-DM1 in patients with HER2-positive mBC or locally advanced BC, and was conducted as a post-approval safety measure to fulfill a commitment to the European Medicines Agency (EMA). Here, ERBB2 is linked to breast cancer.